TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Role of Circulating Innate Lymphoid Cells in Allergic Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Adult subjects between age 19-50 years.~2. Non-smokers, defined as \< 100 cigarettes in lifetime.~Exclusion Criteria:~1. Female donors will be excluded if they are menopausal or have undergone total abdominal hysterectomy and/or bilateral salpingoophorectomy~2. For female donors, blood draw cannot occur during menstrual period time. Subjects will be excluded if they have menstrual period at timing of blood draw.~3. Current and past smokers.~4. Subjects with asthma and any other lung disease including chronic obstructive pulmonary disease, interstitial lung disease, pulmonary hypertension, sarcoidosis, cystic fibrosis.~5. Pregnant or lactating subjects~6. Subjects with hypercalcemia (\> 10.3 mg/dL), renal insufficiency (glomerular filtration rate \[GFR\] \< 50 mL/min/1.73m2), or malignancy.~7. Subjects with any symptoms of respiratory infection in the past 4 weeks.~8. Subjects unable to hold leukotriene modifiers or antihistamines for at least 24 hours prior to blood draw.~9. Subjects on any immunomodulators, including omalizumab, or systemic corticosteroid in the past 4 weeks.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Healthy Control Adult Subjects (Type: None): Healthy adult subjects between the ages of 19-50 years will be enrolled.
- Asthmatic Adult Subjects (Type: None): Adult subjects between the ages of 19-50 years with mild-to-moderate asthma seen within the UNMC Allergy and Pulmonary Clinics will be invited to be enrolled.
- Chronic Urticaria Adult Subjects (Type: None): Adult subjects between the ages of 19-50 years with chronic urticaria seen within the UNMC Allergy Clinics will be invited to be enrolled.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Photodynamic Therapy (PDT) Versus Transpupillary Thermotherapy (TTT) in Occult Choroidal Neovascularization (CNV) in Age-related Macular Degeneration (AMD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* \> 55 years of age,~* Subfoveal occult only CNV due to AMD,~* \< 4 disc areas or \> 4 disc areas~* VA \< 0.4~Exclusion Criteria:~* Sign of classic CNV,~* CNV in other diagnoses than AMD,

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Estrogen Replacement to Reduce Risk of Neurologic Injury After Coronary Artery Bypass Graft Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients whose scheduled procedure is CABG surgery OR~* Patients whose scheduled procedure is isolated aortic surgery OR~* Patients whose scheduled procedure is mitral valve surgery OR~* Patients whose scheduled procedure is CABG combined with aortic or mitral valve surgery~Exclusion Criteria:~* Patients having re-operations~* Patients having combined carotid endarterectomy with CABG surgery~* Patients having CABG with tricuspid valve surgery~* Patients having mitral and aortic valvular surgery (with or without CABG surgery)~* Elevation of liver function test before surgery or creatinine before surgery greater than 2 mg/dl~* Emergency surgery~* Severe cognitive impairment before surgery as indicated by clinical history and/or a score greater than 12 on the Short Blessed Dementia Screening Test (see d11)~* Inability to attend outpatient visits~* A history of venous thromboembolism~* Unexplained vaginal bleeding~* A history of breast cancer or personal history of endometrial cancer in the absence of hysterectomy~* Estrogen use within 6 months of the surgery~* Patient refusal to participate~* Inability to speak and read English or visual impairment

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of GORE® BIO-A® Fistula Plug for Use in Anal Fistula Repair

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Transsphincteric fistula consisting of 1 tract(defined as a fistula which would not be amenable to fistulotomy); determined during operative procedure~* Likely cryptoglandular origin~* Must be at least 18 years of age~* Patients informed about the study, and will have read, understood and signed the patient informed consent and authorization to use PHI data, as applicable~* Patients willing and able to submit to postoperative follow-up evaluations~Exclusion Criteria:~* Crohn's Disease~* Evidence of on-going local infection~* History of more than 2 prior definitive repair attempts; repair attempt is defined as any of the following: advancement flap, cutting seton, fistulotomy, fistulectomy, fibrin glue, anal fistula plug, LIFT~* Superficial fistulas without any muscle involvement~* Fistulae of traumatic origin, including obstetric~* Intersphincteric fistulas that would be candidate for fistulotomy~* Horseshoe or multi-tract fistulas~* Ano-vaginal or recto-vaginal fistulas~* Anastomotic fistulas (ileo-anal, colo-anal)~* A wound-healing or autoimmune disorder (including insulin-dependent diabetics)~* Subjects who are immunocompromised such as, with HIV, or currently receiving chemo or radiation therapy~* Subjects who are immunosuppressed, e.g. transplant patients, patients taking steroids, TNF agents, methotrexate~* History of prior or current pelvic radiation~* Difficulty comprehending or complying with the study (in surgeon's opinion)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GORE® BIO-A® Fistula Plug (Type: None): All patients in study receive the GORE® BIO-A® Fistula Plug.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Male or female patients, aged ≥ 18.~2. Willing and able to give written, informed consent.~3. Confirmed diagnosis of MM.~4. Measurable disease as defined by IMWG.~5. Relapse or refractory disease and have had at least 3 different prior lines of therapy including proteasome inhibitor, alkylator and immunomodulatory therapy (IMiD), or have double refractory disease to a proteasome inhibitor and IMiD.~6. For females of childbearing potential, a negative serum or urine pregnancy test must be documented at screening and confirmed before receiving study treatment.~7. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1.~8. Peripheral blood total lymphocyte count \> 0.5 x 10⁹/L.~Key Exclusion Criteria:~1. Women who are pregnant or lactating.~2. Prior treatment with investigational or approved gene therapy or cell therapy products.~3. Patient has previously received an allogenic stem cell transplant.~4. Clinically significant, uncontrolled heart disease or a recent (within 6 months) cardiac event.~5. Left Ventricular Ejection fraction \< 50 unless the institutional lower limit of normal is lower.~6. Significant liver disease: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 3 × ULN, or total bilirubin \> 2.0 mg/dL or evidence of end stage liver disease (e.g. ascites, hepatic encephalopathy).~7. Chronic renal impairment requiring dialysis, or calculated creatinine clearance \< 30 mL/min~8. Active infectious bacterial or viral disease (hepatitis B virus, hepatitis C virus, human immunodeficiency virus, human T-lymphotropic virus or syphilis) requiring treatmenUse of rituximab within the last 3 months.~9. Active autoimmune disease requiring immunosuppression.~10. Received any anti-myeloma therapy within the last 21 days prior to preconditioning or 10 days prior to leukapheresis; steroids of up to 160 mg of dexamethasone are permitted so long as \> 7 days post-dose prior to pre-conditioning or leukapheresis.~11. Known allergy to albumin, dimethyl sulfoxide (DMSO), cyclophosphamide or fludarabine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AUTO2 (Type: EXPERIMENTAL): Relapsed or refractory Myeloma patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Atrial Fibrillation Registry in Jordan

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Admission with atrial fibrillation~* developing atrial fibrillation during hospitalization for mon AF reason.~* age 18 or more years.~* patients welling to participate in the registry.~Exclusion Criteria:~* age less than 18 years.~* patients not welling to participate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- AF cohort (Type: None): AF consecutive patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Benzodiazepines for the Reduction of Distress and Pain During and After Emergency Department Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults between the ages of 18-65~* Sustained a physical injury with a pain score ≥ 5 on the numeric rating scale \[NRS\] from 0- 10 with anchors of 0 = no pain and 10 = worst pain imaginable~* Expected to be in the ED for at least 2 hours, in a private treatment room~* Ownership of a cell phone with text messaging capabilities~* Emergency Department admission assessment confirmed subject is not suicidal.~Exclusion Criteria:~* Non-English speaking~* Not medically suitable for lorazepam per treating MD (e.g. medical condition where benzodiazepines are contraindicated or may be unsafe)~* Not alert and oriented~* Active psychosis, self-injury, suicidal/homicidal intentions on initial evaluation by treating team~* Seeking treatment due to a mental health or substance use disorder~* History of chronic opioid use~* Prescribed opioid or benzodiazepine use within the past 24 hours~* Alcohol use within the past 12 hours or medical history of alcoholism.~* Clinical indication for open-label benzodiazepine administration in the ED.~* Any use of recreational narcotics throughout lifetime~* Sensitivity or allergy or intolerance to opioids or benzodiazepines~* Current neurological disease (e.g., multiple sclerosis, stroke, brain tumor, seizure disorder, etc.)~* Prisoner

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Drug: Oral Lorazepam (1mg) (Type: EXPERIMENTAL): Lorazepam (Ativan) is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms.
- Drug: Oral Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Tumour Response in Cancer Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) With AMT2003

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Cancer confirmed by histology or cytology~* At least one measurable lesion~* Advanced disease refractory to standard therapy or for which no standard therapy exists~* Life expectancy of at least 3 months~Exclusion Criteria:~* Known secondary neoplasia or central nervous system (CNS) metastases; acute or chronic leukemia, lymphoma or multiple myeloma~* Body weight below 45 kg~* Female patients who are pregnant or breast feeding or adults of reproductive potential not employing effective method of birth control~* Confirmed diagnosis of HIV~* Insulin dependent diabetes mellitus / abnormal glucose tolerance test (GTT) / latent diabetes mellitus type I or II~* Chemotherapy or radiotherapy less than 4 weeks prior to entry~* Surgery less than 2 weeks prior to entry (or not recovered from effects of surgery)~* Participation in a clinical trial less than 30 days prior to entry into study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- AMT2003 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Before the beginning of the specific protocol procedures must be obtained and documented a written consent form. Patients must have sufficient capacity to understand and sign the consent form.~* Exocrine pancreatic potentially resectable carcinoma, histologically confirmed.~* Aged 18-75 years.~* OMS functional state (FE) from 0-2 and Karnofsky functional state 70%.~* Radiologically or measurable disease, defined as borderline resectability disease.~* Appropriate biological parameters: neutrophils \> 1.500/mL; platelets \> 100.000/mL; hemoglobin \> 10 g/dl.Serum creatinine \< 1,5 x upper limit of normal (LSN); alkaline phosphatase \< 3 x LSN and bilirubin \< 1,5 x LSN; AST and ALT 2,5 x LSN.~* Controlled biliary obstruction in all the patients before their inclusion in the study.~* Absence of peripheral neuropathy grade 2.~* Life expectancy of at least 3 months.~Exclusion Criteria:~* Previous administration of chemotherapy, radiotherapy or any investigational agents for pancreatic cancer treatment.~* Administration of other experimental treatment during this study or in the previous 6 months.~* Pregnancy, inappropriate or unsafe use of contraceptive methods or women who are breast-feeding.~* Clinically significant heart disease(for example: congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not properly controlled with medication or myocardial infarction in the last 12 months).~* Presence of significant ophthalmologic anomaly, included: severe dry eye syndrome, Sjogren syndrome, dry keratoconjunctivitis, severe exposure keratopathy, conditions that might increase the risk of epithelium complications.~* Patients with lack of physical integrity of the upper gastrointestinal tract or bad absorption syndromes or unable to ingest the tablets.~* Other previous bad or concurrent diseases, with the exception of nonmelanoma skin cancer.~* Medical or psychiatric pathologies that are severe or uncontrolled.~* Distant metastases.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- QT + QRT (Type: EXPERIMENTAL): Chemotherapy (6 cycles x 14 days): Gemcitabine 1000 mg/m2 (day 1) + Oxaliplatin 100 mg/m2 (day 2) + Tarceva 100 mg/day.~Chemoradiotherapy (5,5 weeks): Gemcitabine 40 mg/m2 (2 days/week) + Tarceva 100 mg/day + Radiotherapy (1,8 Gy/day x 28 doses, total dose: 50,4 Gy).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Primary Prophylaxis for Spontaneous Bacterial Peritonitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Decompensated liver cirrhosis (Childs B \& C) with ascites.~* Established diagnosis of SIBO~Exclusion Criteria:~* Known allergy to treatment drugs~* Inability to undergo test confirm the success of SIBO eradication;~* Pregnant or lactating women~* Terminal malignancy.~* Untreated Viral Hepatitis~* Alcoholic Liver disease with ongoing drinking.~* Respiratory Failure~* Recent antibiotics and proton-pump inhibitor within 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Control arm (Type: NO_INTERVENTION): Standard of care
- Treatment arm (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed primary squamous cell carcinoma or adenocarcinoma of the thoracic esophagus (≥ 20 cm from the incisors\*) or the gastroesophageal junction (confined to ≤ 2 cm into the gastric cardia)~  * Disease confined to the esophagus or peri-esophageal soft tissue~ * T4, M0 disease~ * Surgically unresectable disease by esophageal endoscopic ultrasonography OR medically unresectable disease~NOTE: \*Patients with primary disease \< 26 cm from the incisors must undergo bronchoscopy AND have negative cytology within the past 4 weeks~* Measurable or non-measurable disease by x-ray, CT scan and/or MRI, or physical examination within the past 4 weeks (for measurable disease) or within the past 6 weeks (for non-measurable disease)~* Tumor specimens available~* No recurrent disease~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Zubrod 0-2~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count (ANC) ≥ 1,500/mm\^3~* White Blood Cell (WBC) count ≥ 3,000/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 10.0 g/dL~Hepatic~* Albumin normal~* Bilirubin normal~* Alkaline phosphatase normal~* Serum glutamic oxaloacetic transaminase (SGOT) or Serum glutamic pyruvic transaminase (SGPT) ≤ 2.5 times upper limit of normal~Renal~* Creatinine clearance \> 50 mL/min~Other~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No prior severe reaction to monoclonal antibodies~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No prior chemotherapy for esophageal cancer~Endocrine therapy~* Not specified~Radiotherapy~* No prior radiotherapy for esophageal cancer~* No concurrent intensity modulated radiotherapy~* No concurrent cobalt-60~Surgery~* No prior surgical resection or attempted surgical resection of esophageal cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Cetuximab+Cisplatin+Irinotecan followed by radiation therapy (RT) in Cycle 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Low Dose Vasopressin in Traumatic Shock

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~To be eligible for enrollment in the study, a patient must meet all of the follow criteria at assessment:~* Patient is a male or female patient presumed to be at least 18 years of age;~* Patient has a systolic blood pressure \< 90 mmHg;~* Patient has clinical evidence of acute traumatic injury;~* Infusion of study drug must start within one hour following SBP (systolic blood pressure) \< 90 mmHg~Exclusion Criteria:~A patient meeting any one of the following criteria at hospital assessment is not eligible for enrollment:~* Patient is admitted to one of the study hospitals' Emergency Department greater than six hours after injury;~* Patient has received greater than 4 liters fluid since time of injury;~* Patient is enrolled in another shock trial;~* Patient is asystolic or requires CPR (cardiopulmonary resucitation) prior to randomization;~* Female patient is pregnant by report or suspicion;~* Patient has known Do Not Resuscitate orders or visible/identifiable method of objection to participation (e.g., exclusion bracelet);

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- I (Type: EXPERIMENTAL): Vasopressin
- 2 (Type: PLACEBO_COMPARATOR): bolus of NS (normal saline) followed by continuous infusion of NS, no vasopressin added

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues